AstraZeneca Reports the P-III (FLAURA2) Study Results Evaluating Tagrisso Plus Chemotherapy to Treat Advanced Lung Cancer
Shots:
- The P-III (FLAURA2) study assesses Tagrisso (80mg, QD, oral) + CT (pemetrexed: 500mg/m^2 + cisplatin: 75mg/m^2 or carboplatin), Q3W followed by Tagrisso with pemetrexed maintenance as a 1L treatment of patients (n=557) with locally advanced (stage IIIB-IIIC) or metastatic (stage IV) EGFRm NSCLC
- The study depicted an improved PFS & a favorable trend in the OS interim results at 41% data maturity with consistent outcomes in the subgroups such as sex, race, type of EGFRm & age. Further OS evaluation continues for the final analysis
- The combination of Tagrisso & CT also demonstrated consistent benefit in time to first subsequent treatment, time to progression on 2L therapy & time to 2nd subsequent treatment
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Tagrisso Receives Approval from the US FDA for the Treatment of Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
